Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print COX-2 Inhibitors Significantly Reduce Risk of Cancer

COX-2 Inhibitors Significantly Reduce Risk of Cancer

April 04, 2006

WASHINGTON, D.C. - Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.




"We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer," says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.

The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.

Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.

They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.

They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.

On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provided no significant change in the risk of breast cancer.

"The COX-2 signaling pathway is important in cancer because when it's activated, it can stimulate many key steps in cancer development, including cell division, inhibition of cell death, angiogenesis (the creation of new blood vessels to nourish growing tumors) and metastasis," says Harris, who is also a member of the OSU Comprehensive Cancer Center.

Harris says his research group is only midway through analyzing data from the other parts of the study, but adds that early results suggest that regular use of selective COX-2 inhibitors appears to provide about the same magnitude of protection from prostate, lung and colon cancer.

"These results suggest strong potential for regular use of these drugs in cancer prevention. Still, we know these drugs may have side effects, so we are not advising people to go out and start taking them until more studies confirm that they are safe and effective," says Harris.

Celebrex is still widely used for pain relief, but Vioxx was pulled off the market in 2004 following reports of heightened risk of heart attacks.

"It's clear that we need to have multiple retrospective and prospective studies to validate these findings," says Harris, who has been studying the impact of COX-2 inhibitors for many years. "Eventually, we may find that regular intake of a low dose of a COX-2 inhibitor may be enough to reset the COX-2 cascade and safely protect people against cancer."

Grants from Pfizer and the National Cancer Institute supported the study.

Study co-authors include Joanne Beebe-Donk and Galal Alshafie, both colleagues in the Center for Molecular Epidemiology and Environmental Health in the OSU College of Medicine.

The Ohio State University Medical Center



Related Cox-2 Inhibitors News Articles Cox-2 Inhibitors News and Current Cox-2 Inhibitors Events RSS Cox-2 Inhibitors News and Current Cox-2 Inhibitors Events RSS
Brain study may lead to improved epilepsy treatments
Using a rodent model of epilepsy, researchers found one of the body's own neurotransmitters released during seizures, glutamate, turns on a signaling pathway in the brain that increases production of a protein that could reduce medication entry into the brain.

Popular Arthritis Drug May Disrupt Heart Rhythm, UB Research Finds
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.

New study may explain Vioxx side effects
Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people.

COX-2 inhibitors delay pancreatic cancer precursors in mice
Nimesulide, a cyclooxygenase-2 (COX-2) inhibitor, delays the progression of precancerous pancreatic lesions in mice, according to researchers at David Geffen School of Medicine at UCLA.

Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage
Early-stage research has found that a new gene therapy can nearly eliminate arthritis pain, and significantly reduce long-term damage to the affected joints, according to a study published today in the journal Arthritis and Rheumatism.

Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
A colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical science should employ aspirin and new aspirin-like drugs for use in preventing colon cancer in certain high-risk individuals.

FDA causes unnecessary scare about common painkillers
The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe.

Ibuprofen puts high risk cardiac patients at risk
Doctors who treat the painful condition of osteoarthritis in patients with increased cardiovascular risk need to be cautious. A team lead by researchers at Mount Sinai School of Medicine, are the first to study outcomes in high cardiovascular risk patients with osteoarthritis.

Ibuprofen may boost chance of heart problems in high risk patients with osteoarthritis
The common painkiller, ibuprofen, may boost the likelihood of heart problems in high risk patients who have osteoarthritis, suggests research published ahead of print in the Annals of the Rheumatic Diseases.

Green tea and COX-2 inhibitors combine to slow growth of prostate cancer
Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.
More Cox-2 Inhibitors News Articles


The Cox-2 Connection: Natural Breakthrough Treatments for Arthritis, Alzheimer's, and Cancer
by James B. LaValle

All of us have experienced, at one time or another, the temporary inflammation and pain of a minor injury. But those who suffer from chronic inflammation--whether the result of an injury or a biological disorder--and its coincidental pain are all too aware of the frequently crippling and debilitating effects of these conditions.  In The Cox-2 Connection, pharmacist and naturalist James B. LaValle...



COX-2 Inhibitors (Milestones in Drug Therapy)

COX-2 inhibitors are important drugs with analgesic and anti-inflammatory effects. The discovery of COX-2, the evolution of drug development in this field and the implications of these developments in patient therapy are topics of this volume. This book presents both pre-clinical and clinical information and is important for clinicians interested in the latest information about this class of...

The New NSAIDs: Cox-2 Inhibitors.: An article from: MedSurg Nursing
by Teri Capriotti

This digital document is an article from MedSurg Nursing, published by Jannetti Publications, Inc. on December 1, 2000. The length of the article is 3317 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...



Clinical Significance And Potential Of Selective Cox-2 Inhibitors
by Sir John, Ed. Vane

NSAIDs: Drug of Choice for Severe Osteoarthritis.(Brief Article): An article from: Family Practice News
by Timothy F. Kirn

This digital document is an article from Family Practice News, published by International Medical News Group on February 15, 2001. The length of the article is 727 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Search Continues for Anti-Inflammatory Therapy for Alzheimer's.: An article from: Family Practice News
by Jennifer M. Wang

This digital document is an article from Family Practice News, published by International Medical News Group on April 15, 2000. The length of the article is 589 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

COX-2 inhibitors: what you need to know.: An article from: National Women's Health Report

This digital document is an article from National Women's Health Report, published by Thomson Gale on June 1, 2005. The length of the article is 693 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Studies show no extra CV events with COX-2 drugs: less than 1% of patients in either therapy arm stopped therapy due to hypertension. (Much Debated Issue).(cardiovascular ... An article from: Family Practice News
by Bruce Jancin

This digital document is an article from Family Practice News, published by International Medical News Group on May 15, 2003. The length of the article is 625 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Cost of COX-2 Inhibitors Offset by Decline in GI Procedures.(Brief Article): An article from: Family Practice News
by Bruce Jancin

This digital document is an article from Family Practice News, published by International Medical News Group on February 15, 2001. The length of the article is 747 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

NSAIDs may complicate heart failure. (Renal Blood Flow Diminished).(Brief Article): An article from: Internal Medicine News

This digital document is an article from Internal Medicine News, published by International Medical News Group on May 1, 2002. The length of the article is 609 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com